The composition of Graftide is an active substance of mycophenolate mofetil . Additional ingredients: pregelatinized starch, povidone, croscarmellose sodium, magnesium stearate, microcrystalline cellulose.
Graftide Tablet The active substance of this preparation is 2-morpholinoethyl ester of mycophenolic acid . As is known, mycophenolic acid, in turn, is a powerful selective non-competitive and reversible inhibitor of inosine monophosphate dehydrogenase. It is he who is able to suppress the production of guanosine nucleotides. Also, the oxidation of inosine monophosphate to xanthose-5-monophosphate is prevented. This acid exhibits a sufficiently pronounced cytostatic effect on lymphocytes, as compared to other cells, since the proliferation of T and B lymphocytes largely depends on the formation of de novo purines, and other types of cells switch to other metabolic pathways .
As a preventive measure for rejection of transplanted organs: the kidney, heart or liver, as well as the therapy of refractory kidney rejection after transplantation, the drug is prescribed as part of a complex treatment with antitumocyte globulin, Ciclosporin , Muromonab-SD3 and corticosteroids . Thanks for taking this medication, the frequency of ineffective treatment decreases in the first six months, from the moment of transplantation and the possible rejection of organs.
Inside the human body, the drug undergoes rapid and complete absorption. As a result of metabolism, an active metabolite is formed in the form of mycophenolic acid. Distribution occurs in tissues, organs, and physiological fluids, 97% binding to blood plasma. From the body, the drug is excreted mainly in urine and a small part of feces.
Indications for use
The drug is prescribed as part of a comprehensive treatment with corticosteroids and Ciclosporin as a prophylaxis for acute organ rejection and:
- treatment of their refractory rejection in patients after allogeneic renal transplantation;
- improved survival of transplants and patients who underwent allogeneic heart transplant;
- after allogenic liver transplantation.
The major side effects that may accompany the use of Graftide with corticosteroids and cyclosporin as preventing the rejection of transplanted organs are the following: diarrhea, sepsis, leukopenia, vomiting and the development of opportunistic infections, and other disorders.
In clinical practice, cases of overdose have not been established, but they should not be excluded. At the same time, the expected symptoms are immunosuppression, which increases the sensitivity to various infections, and bone marrow suppression.
The main treatment requires stopping or reducing the dosage of the drug, followed by the appointment of symptomatic therapy.
The combination of the drug with acyclovir m can increase the concentration of each agent in the composition of the plasma with renal failure.
Antacids, which contain magnesium hydroxide or aluminum, can reduce the absorption of mycophenolate mofetil.
Simultaneous admission with Tacrolimus can lead to a change in the concentration of mycophenolic acid. The tubular secretion blockers can increase its concentration.
During the treatment, the introduction of live vaccines is not recommended, since this can lead to a significant decrease in antibody formation.